Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT02244489 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Momelotinib (MMB)
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Sierra Oncology LLC - a GSK company